Drug Approval | November 14, 2022
Stelis receives recommendation from EMA granting market authorization for Kauliv
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
The company is making its entry into the Hyderabad market through its unique asset-light business model
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
The dividend cheque of Rs. 9.93 crore for the Ministry of Ayush was handed over to Sonowal
Dr. Mandaviya agreed to host the Stop TB Partnership’s 36th Board meeting on March 25-26, 2023 in Varanasi
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
The Group will continue to make proactive investments of its management resources in the life science business
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
Subscribe To Our Newsletter & Stay Updated
